Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kalbe Farma TbkFRA:LCLA 77 EV-to-EBITDA is 5.58 as of Aug. 05, 2026, which is 68% below its 10-year median of 17.39. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.10 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 745 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 81.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Kalbe Farma Tbk's enterprise value is €1,473 Mil.
PT Kalbe Farma Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €264 Mil. Therefore, PT Kalbe Farma Tbk's EV-to-EBITDA for today is 5.58.
The historical rank and industry rank for PT Kalbe Farma Tbk's EV-to-EBITDA or its related term are showing as below:
FRA:LCLA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.53 Med: 17.39 Max: 26.66
Current: 5.9
During the past 13 years, the highest EV-to-EBITDA of PT Kalbe Farma Tbk was 26.66. The lowest was 5.53. And the median was 17.39.
FRA:LCLA's EV-to-EBITDA is ranked better than 81.88% of 745
companies
in the Drug Manufacturers industry
Industry Median: 13.04
vs FRA:LCLA: 5.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Kalbe Farma Tbk's PE Ratio (TTM) for today is calculated as:
PT Kalbe Farma Tbk's share price for today is €0.027.
PT Kalbe Farma Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PT Kalbe Farma Tbk's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's EV-to-EBITDA falls into.
PT Kalbe Farma Tbk's current Enterprise Value is €1,473 Mil.
PT Kalbe Farma Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €264 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kalbe Farma Tbk (FRA:LCLA) has a EV-to-EBITDA of 5.58 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Kalbe Farma Tbk. This is 68% below median its historical median of 17.39. Over the past decade, PT Kalbe Farma Tbk's EV-to-EBITDA has ranged from 5.53 to 26.66. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #135 out of 745 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is PT Kalbe Farma Tbk's EV-to-EBITDA too high?
PT Kalbe Farma Tbk's current EV-to-EBITDA of 5.58 is 68% below median its 10-year median of 17.39. Over the past 10 years, this metric has ranged from a low of 5.53 to a high of 26.66. The Drug Manufacturers industry median EV-to-EBITDA is 13.04. PT Kalbe Farma Tbk's value of 5.58 is 57.2% below this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #135 out of 745 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #135 out of 745 companies for EV-to-EBITDA. This places PT Kalbe Farma Tbk in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.04. PT Kalbe Farma Tbk's value of 5.58 is 57.2% below this benchmark. Historically, PT Kalbe Farma Tbk's own EV-to-EBITDA has ranged from 5.53 to 26.66 over the past decade. While the company's 10-year median is 17.39 vs. the industry median of 13.04, PT Kalbe Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.04, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current EV-to-EBITDA of 5.58 is 57.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Kalbe Farma Tbk. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current EV-to-EBITDA is 5.58, which is 68% below median its own 10-year median of 17.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.03 — trading 73% below its estimated fair value. The current EV-to-EBITDA is 5.58, which is 68% below median its 10-year median of 17.39 and 57.2% below the Drug Manufacturers industry median of 13.04. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current EV-to-EBITDA is 5.58 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 73% below its estimated GF Value™ of €0.10.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
EV-to-EBITDA: 5.58 (68% below median its 10-year median of 17.39)
GF Value™: €0.10 vs. price of €0.03 (73% below fair value)
Industry Position: 57.2% below the Drug Manufacturers median (#135 of 745)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
